News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mylan Inc. (MYL), Agila Told by Federal Trade Commission to Shed 11 Generics for Merger


9/27/2013 7:33:30 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Mylan Inc. (MYL) and Agila Specialties Pvt. must divest 11 injectable generic drugs in order to win approval for their proposed merger from the U.S. Federal Trade Commission, the agency said in a statement. The FTC said the transaction as originally proposed would have hurt competition for the drugs in 11 markets where Mylan and Agila are two of a limited number of competitors. “This proposed settlement will ensure that these important generic injectable medications, which are used to treat conditions ranging from heart disease and hypertension to cancer, remain available at a competitive price,” said Deborah Feinstein, director of the FTC’s Bureau of Competition.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg
Read at Reuters
Read at The Deal.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES